Cytomegalovirus Infection Drug Market Pipeline Research Report 2021 -

DUBLIN--()--The "Cytomegalovirus Infection - Pipeline Insight, 2021" clinical trials has been added to's offering.

This Cytomegalovirus infection - Pipeline Insight, 2021 provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Cytomegalovirus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cytomegalovirus infection R&D. The therapies under development are focused on novel approaches to treat/improve Cytomegalovirus infection.

Cytomegalovirus infection Emerging Drugs Chapters

This segment of the Cytomegalovirus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cytomegalovirus infection Emerging Drugs

mRNA-1647: Moderna Therapeutics

mRNA-1647 is a vaccine combining six mRNAs in a single vial, which encode for two antigens located on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB). The vaccine is in Phase II clinical studies for the treatment of CMV.

Maribavir: Takeda

TAK-620 (maribavir), is an investigational, orally bioavailable, ganciclovir kinase inhibitor based antiviral compound. The FDA has granted Maribavir Orphan Drug Designation for the treatment of clinically significant CMV viremia and disease in at-risk patients. The FDA has also granted maribavir Breakthrough Therapy Designation as a treatment for CMV infection and disease in transplant patients resistant or refractory to prior therapy.

In May 2021, Takeda announced that the US Food & Drug Administration (FDA) had accepted a New Drug Application (NDA) for maribavir for the treatment of CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT) or hematopoietic cell transplant (HCT) recipients.

Cytomegalovirus infection: Therapeutic Assessment

This segment of the report provides insights about the different Cytomegalovirus infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cytomegalovirus infection

There are approx. 20+ key companies which are developing the therapies for Cytomegalovirus infection. The companies which have their Cytomegalovirus infection drug candidates in the most advanced stage, i.e. Preregistration include, Takeda.


This report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Cytomegalovirus infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cytomegalovirus infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytomegalovirus infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytomegalovirus infection drugs.

Cytomegalovirus infection Report Insights

  • Cytomegalovirus infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Cytomegalovirus infection Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cytomegalovirus infection drugs?
  • How many Cytomegalovirus infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytomegalovirus infection?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cytomegalovirus infection therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cytomegalovirus infection and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Moderna Therapeutics
  • Takeda
  • AlloVir
  • SpyBiotech
  • Trinomab Biotech
  • Evrys Bio
  • Merck & Co
  • Biotest
  • Stadius Biopharma
  • Citranvi Biosciences
  • Xyphos
  • Orbis Biosciences
  • Nobelpharma
  • Hookipa Biotech
  • AlphaVax, Inc.
  • Trellis Bioscience

Key Products

  • mRNA 1443
  • Maribavir
  • Multivirus-specific cytotoxic T lymphocytes
  • Cytomegalovirus vaccine
  • Anti-human Cytomegalovirus monoclonal antibody

Research programme: sirtuin targeted therapeutics

  • V 160
  • Cytomegalovirus immune globulin

Research Programme: Herpesvirus vaccines

Research programme: MicAbody antibodies

  • Ganciclovir extended release
  • NPC 21
  • HB-101
  • AVX601
  • CMV-345

For more information about this clinical trials report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900